Antibody-Oligonucleotide Conjugation
Antibody-Oligonucleotide Conjugation
Rockland offers custom antibody-oligonucleotide conjugations (AOCs) by common coupling chemistry strategies, producing high-quality, antibody-oligo conjugates as a complete solutions provider to the oligonucleotide therapeutic industry. Our expertise in cross-linking chemistries enable our scientists to effectively conjugate oligonucleotides, regardless of structure or modifications. The resulting conjugates are chemically stable, and suitable for use in in vitro assays, in vivo assays, and immunization studies. Our quality methods can confirm successful antibody-oligo labeling and are included in our custom services.
Antibody-Oligonucleotide Conjugates
Antibody-oligonucleotide conjugates (AOCs) have emerged as a promising approach for targeted drug delivery. By conjugating oligonucleotides such as siRNAs or ASOs to antibodies or antibody fragments, AOCs can selectively bind to specific cell surface antigens and deliver the oligonucleotides to the target cells, resulting in gene silencing or other therapeutic effects. AOCs offer several advantages, such as increased specificity, reduced off-target effects, dose reduction, and improved pharmacokinetics.
However, the development of effective AOCs requires careful consideration of factors such as the choice of antibody or antibody fragment, the selection of conjugation chemistry, the route of antigen internalization, and the need for efficient endosomal escape to achieve therapeutic activity.
Producing high-quality AOCs are the cornerstone of Rockland’s anti-oligonucleotide antibody generation expertise and make us an ideal partner for the development of oligonucleotide-based therapeutics with precise targeting capabilities. From custom conjugation design to quality confirmation, we provide comprehensive solutions to meet your needs.
Available Cross-Linking Chemistries
Antibody-Oligo Conjugates in Immuno-PCR
Leverage Rockland's expertise in nucleic acid conjugation for novel detection assays such as immuno-PCR (iPCR). Immuno-PCR is a powerful detection method that combines the specificity of an antibody with the sensitivity of PCR. In immuno-PCR, the target protein is captured and bound by an antibody that has been conjugated to an oligonucleotide label. The oligonucleotide serves as the target sequence for a subsequent PCR.
Because of the efficiency of nucleic acid amplification, iPCR typically results in a 10- to 1,000-fold increase in sensitivity compared to an analogous enzyme-linked immunoassay. This enables the detection of rare analytes in complex samples that are difficult to detect in conventional immunoassays. Due to the similarity to a sandwich ELISA, virtually any antibody suitable for ELISA can be adapted for immuno-PCR.
Oligo-labeled Antibodies in DNA-PAINT
DNA-PAINT has emerged as a revolutionary technique in the field of molecular imaging, revolutionizing our ability to study intricate biological structures with unprecedented precision. By utilizing oligo-labeled antibodies, this technique harnesses the principles of DNA hybridization and fluorescence microscopy to achieve exceptional spatial resolution and target specificity.
Upon introducing target-specific antibodies labeled with oligos, docking strands with complementary sequences to the oligos are subsequently added. Through reversible binding and unbinding interactions, referred to as "docking" and "undocking" events, fluorescent probes can be repeatedly bound to the target molecule, creating a blinking fluorescence signal. By meticulously analyzing these blinking events, the super-resolution reconstruction of the target molecule can be achieved, surpassing the traditional diffraction limit of microscopy techniques. Moreover, the versatility of DNA-PAINT allows for multiplexed imaging, where distinct targets can be simultaneously imaged. Benefit from first-class antibodies and our antibody-oligonucleotide conjugation expertise here at Rockland and contact us for details.
Interested in antibody-oligonucleotide conjugation?
We can help move your program forward—contact us to find out how.